Teresa Reguly
Teresa Reguly
Partner at Torys LLP
(416) 865-7316
(416) 865-7380
79 Wellington St W, Suite 3000, Box 270, TD Ctr, Toronto, ON
Year called to bar: 2007 (ON)
Practice focuses on advising clients that sell regulated products in the food, pharmaceutical, biotechnology and medical device industries. Advises on intellectual property and regulatory issues, in particular, patent and regulatory matters in the chemical, biochemical and pharmaceutical fields, and has experience with drafting, filing and prosecuting patent applications, and advising on validity, patentability and infringement of intellectual property rights. Also has been involved in drafting and negotiating IP licensing, research and development, co-promotion, marketing and confidentiality agreements for her clients, and provides guidance in Food and Drugs Act compliance, establishment licensing, product licensing, packaging and labelling, drug pricing and formulary listings. Has expertise in advertising and promotion of consumer products, food and health products, as well as mandatory reporting and corrective actions. Also advises clients in a range of industries on privacy issues, cross-border transfer of personal information and compliance with privacy law obligations. A Registered Patent Agent in Canada. Ontario Bar, 2007. JD, 2006, University of Toronto. PhD (Molecular and Medical Genetics), 2003, University of Toronto.
Teresa Reguly is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Repeatedly Recommended
Teresa Reguly is also listed in the following publication(s)
Special Edition Cannabis
Special Edition Health Sciences
Read more about Teresa Reguly in ...
Less Regulation, More Product Pathways?
Critics argue that regulations prevent large food companies from entering the edible cannabis market and that cosmetic and topical products containing cannabis might be best sold in drugstores
On July 17, 2017, Norgine B.V., a European specialist pharmaceutical company, acquired all issued and outstanding shares of Merus Labs International Inc. (Merus), pursuant to a plan of arrangement for $1.65 per common share in cash, including the assumption of all debt obligations, for a total enterprise value of approximately $342 million.